CollPlant Biotechnologies Ltd - ADR

CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. It engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. Its products include VergenixSTR, VergenixFG, and Collink.3D. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REHOVOT, Israel, March 29, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced the appointment of Hugh Evans to its Board of Directors, increasing the board to six independent members. U.S.-based Mr.

CollPlant Appoints Additive Manufacturing Executive, Hugh Evans to Its Board of Directors

REHOVOT, Israel, March 26, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced financial results for the full year ended December 31, 2020 and provided an update on the Company's business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures.

CollPlant Biotechnologies Reports Year End Financial Results for Fiscal Year 2020

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) closed at $12.26 in the latest trading session, marking a -1.84% move from the prior day.

CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) Dips More Than Broader Markets: What You Should Know

Is (CLGN) Outperforming Other Medical Stocks This Year?

Has CollPlant Biotechnologies Ltd. Sponsored (CLGN) Outpaced Other Medical Stocks This Year?

Cirrus Logic

HighPoint Resources

Immersion

Suburban Propane Partners

State Auto Financial

Are you going to sit around to try and price a bottom or are you going to grab stocks that look obviously cheap today?

6 Beaten Down Stocks with Solid Growth Potential

REHOVOT, Israel, March 4, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced that Mr. Yehiel Tal, Chief Executive Officer of CollPlant, will provide an overview of the company at the H.C. Wainwright Global Life Sciences...

CollPlant To Present at the H.C. Wainwright Global Life Sciences Conference

REHOVOT, Israel, Feb. 25, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) a regenerative and aesthetics medicine company, today announced that on February 24, 2021 it received a notice from Lung Biotechnology, a United Therapeutics subsidiary, informing the Company of the...

Termination of Licensing Agreement for Bioprinting of Scaffolds for Lung Transplants

REHOVOT, Israel, Feb. 18, 2021 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies (NASDAQ:CLGN), today announced that it has closed the previously announced registered direct offering for the purchase and sale of an aggregate of 2,000,000 of the Company's American Depositary Shares (ADSs), at a purchase price of $17.50 per ADS. Each ADS represents one (1) ordinary share, par value NIS 1.50 per share, of CollPlant.

CollPlant Announces Closing of $35.0 Million Registered Direct Offering of American Depositary Shares

Corvus Pharmaceuticals

Prothena

Corvus Pharmaceuticals (NASDAQ: CRVS) shares are trading lower Friday after the company priced its 8.571 million share common stock offering at $3.50 per share. Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company.

Why Corvus Pharmaceuticals, Prothena, CollPlant Are Moving Today

REHOVOT, Israel, Feb. 11, 2021 (GLOBE NEWSWIRE) -- CollPlant Biotechnologies (NASDAQ:CLGN), today announced that it has entered into definitive agreements with several healthcare-focused and other institutional investors for the purchase and sale of 2,000,000 of the Company's American Depositary Shares (ADSs), at a purchase price of $17.50 per ADS, in a registered direct offering. Each ADS represents one (1) ordinary share, par value NIS 1.50 per share, of CollPlant. The offering is expected to close on or about February 17, 2021, subject to satisfaction of customary closing conditions.

CollPlant Announces $35.0 Million Registered Direct Offering of American Depositary Shares

REHOVOT, Israel, Feb. 8, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) today announced it has entered into a worldwide exclusive development and commercialization agreement for dermal and soft tissue filler products with Allergan Aesthetics, an AbbVie company. CollPlant...

CollPlant Announces Development and Global Commercialization Agreement with Allergan Aesthetics, an AbbVie company, for rhCollagen in Dermal and Soft Tissue Filler Products

REHOVOT, Israel, Nov. 10, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative medicine company, today announced its development program of an antiviral agent for potential treatment of COVID-19 patients. In-vitro early results of CollPlant's formulations showed significant...

CollPlant Announces Early Development Program of Antiviral Agent for Potential Treatment of COVID-19 Patients

REHOVOT, Israel, Sept. 16, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr.

CollPlant Biotechnologies Presents on the Use of Novel, Plant-Derived, Recombinant Human Collagen for Anti-Aging Therapies at the Science of Aging Virtual Symposium 2020

REHOVOT, Israel, Aug. 31, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) a regenerative and aesthetic medicine company, today announced that Dr.

CollPlant Biotechnologies to Present at Science of Aging Virtual Symposium 2020 During Healthy Aging Month

REHOVOT, Israel, Aug. 28, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the second quarter ended June 30, 2020 and provided an update on the Company's business developments.

CollPlant Biotechnologies Reports Second Quarter (Q2) 2020 Financial Results

Is  (CLGN) Outperforming Other Medical Stocks This Year?

Has CollPlant Holdings Ltd. Sponsored (CLGN) Outpaced Other Medical Stocks This Year?

Is CollPlant Holdings Ltd. Sponsored (CLGN) Outperforming Other Medical Stocks This Year?

CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

What Makes CollPlant Holdings Ltd. Sponsored ADR (CLGN) a New Strong Buy Stock

REHOVOT, Israel, May 27, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the first quarter ended March 31, 2020 and provided an update on the Company's business developments. Certain metrics, including...

CollPlant Biotechnologies Reports First Quarter (Q1) 2020 Financial Results

As of late, it has definitely been a great time to be an investor in CollPlant Biotechnologies.

CollPlant's Shares March Higher, Can It Continue?

Quest Diagnostics

DaVita

Natera

Novo Nordisk

ResMed

Zoetis

These healthcare stocks have great financials now, and in the future. They all represent the future of medicine, and offer big growth.

7 Healthcare Stocks Worth Your Time Now

CollPlant Holdings Ltd. Sponsored ADR (CLGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

CollPlant Holdings Ltd. Sponsored ADR (CLGN) Upgraded to Buy: Here's What You Should Know

News for CollPlant Biotechnologies Ltd - ADR Stock (CLGN)